Metallic nanoparticles and treatment of cutaneous leishmaniasis: A systematic review

Guerra, Rhanoica Oliveira; do Carmo Neto, José Rodrigues; da Silva, Priscilla Elias Ferreira; Franco, Pablo Igor Ribeiro; Barbosa, Rafaela Miranda; de Albuquerque Martins, Tarcísio; Costa-Madeira, Juliana; de Assunção, Thais Soares Farnesi; de Oliveira, Carlo José Freire; Machado, Juliana Reis; Silva Teixeira, Luciana de Almeida; Rodrigues, Wellington Francisco; Júnior, Virmondes Rodrigues; Silva, Anielle Christine Almeida; da Silva, Marcos Vinicius

doi:10.1016/j.jtemb.2024.127404

Cited by 4 publications

(1 citation statement)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The last few decades have seen a major impact on this search for new therapies for leishmaniasis and Chagas disease. This research has mainly focused on pharmacological repurposing or the development of new compounds, both of natural and synthetic origin, in addition to other more novel lines such as nanotechnology [8,9] or immunotherapy [10]. The compounds of natural origin discovered in this period include lignans from Piper jericoense [11], sesquiterpenoids and flavonoids from Inula viscosa [12], indolocarbazoles from Streptomyces sanyensis [13], celastroloids from Maytenus chiapensis [14], or extracts from microalgae, such as Chlorella vulgaris [15].…”

Section: Introductionmentioning

confidence: 99%

Global Health Priority Box: Discovering Flucofuron as a Promising Antikinetoplastid Compound

Bethencourt-Estrella,

López-Arencibia,

Lorenzo-Morales

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Leishmaniasis, produced by Leishmania spp., and Chagas disease, produced by Trypanosoma cruzi, affect millions of people around the world. The treatments for these pathologies are not entirely effective and produce some side effects. For these reasons, it is necessary to develop new therapies that are more active and less toxic for patients. Some initiatives, such as the one carried out by the Medicines for Malaria Venture, allow for the screening of a large number of compounds of different origins to find alternatives to the lack of trypanocide treatments. In this work, 240 compounds were tested from the Global Health Priority Box (80 compounds with confirmed activity against drug-resistant malaria, 80 compounds for screening against neglected and zoonotic diseases and diseases at risk of drug resistance, and 80 compounds with activity against various vector species) against Trypanosoma cruzi and Leishmania amazonensis. Flucofuron, a compound with activity against vectors and with previous activity reported against Staphylococcus spp. and Schistosoma spp., demonstrates activity against L. amazonensis and T. cruzi and produces programmed cell death in the parasites. Flucofuron seems to be a good candidate for continuing study and proving its use as a trypanocidal agent.

show abstract

Section: Introductionmentioning

confidence: 99%

Global Health Priority Box: Discovering Flucofuron as a Promising Antikinetoplastid Compound

Bethencourt-Estrella,

López-Arencibia,

Lorenzo-Morales

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

A Comparative Study of Green and Chemically Prepared PEGylated Zinc Sulfide Nanoparticles (ZnS‐NPs) for Biological Applications

Rehman,

Khan,

Jathoi

et al. 2024

ChemistrySelect

View full text Add to dashboard Cite

This study compares chemical and green synthesized zinc sulfide nanoparticles for multiple biological properties. A chemical synthesis approach is utilized to synthesize PEGylated ZnS‐NPs while the bulbs of Fritillariae cirrhosae bulbus are utilized for green synthesis. After extensive characterization, the NPs are examined for multifunctional biological properties such as antimicrobial, antioxidant, in vitro anticancer, and blood compatibility. Our study found that chemical synthesis results in higher yield and better dispersion behavior. However, the green ZnS‐NPs possessed increased antibacterial and antiparasitic potential against Leishmania tropica as the NPs resulted in significant inhibition against Staphylococcus aureus (S. aureus) and Bacillus subtilis (B. subtilis) with minimum inhibitory concentration (MIC) of 0.156 and 0.312 mg/mL, respectively while IC50 of 115.21 and 128.5 µg/mL were observed for the promastigote and amastigote forms of parasite. Furthermore, Fritillaria cirrhosa (F. cirrhosa) synthesized NPs possessed slightly improved antioxidant properties and in vitro anticancer potential against MCF‐7 breast cancer cells. Despite differences in the biological properties, the NPs did not result in hemolytic behavior thus demonstrating the compatible nature against blood cells. It was thus evident from the present study that the chemical and green synthesis techniques not only result in NPs with different physicochemical characteristics but also significantly influence the bio‐interaction of the obtained ZnS‐NPs.

show abstract

Advancing gastric cancer treatment: nanotechnology innovations and future prospects

Yang,

Guo

2024

Cell Biol Toxicol

View full text Add to dashboard Cite

Gastric cancer (GC) is the fifth most common cancer worldwide, particularly prevalent in Asia, especially in China, where both its incidence and mortality rates are significantly high. Meanwhile, nanotechnology has demonstrated great potential in the treatment of GC. In particular, nanodrug delivery systems have improved therapeutic efficacy and targeting through various functional modifications, such as targeting peptides, tumor microenvironment responsiveness, and instrument-based methods. For instance, silica (SiO 2 ) has excellent biocompatibility and can be used as a drug carrier, with its porous structure enhancing drug loading capacity. Polymer nanoparticles regulate drug release rates and mechanisms by altering material composition and preparation methods. Lipid nanoparticles efficiently encapsulate hydrophilic drugs and promote cellular uptake, while carbon-based nanoparticles can be used in biosensors and drug delivery. Targets such as integrins, HER2 receptors, and the tumor microenvironment have been used to improve drug efficacy in GC treatment. Nanodrug delivery techniques not only enhance drug efficacy and delivery capabilities but also selectively target tumor cells. Currently, there is a lack of systematic summarization and synthesis regarding the relationship between nanodrug delivery systems and GC treatment, which to some extent hinders researchers and clinicians from efficiently searching for and referencing related studies, thereby reducing work efficiency. This study aims to systematically summarize the existing research on the relationship between nanodrug delivery systems and GC treatment, making it easier for professionals to search and reference, and thereby promoting further research on the role of nanodrug delivery systems and their clinical applications in GC. This review discusses the applications of functionalized nanocarriers in the treatment of GC in recent years, including surface modifications with targeted markers, the combination of phototherapy, chemotherapy, and immunotherapy, along with their advantages and challenges. It also examines the future prospects of targeted nanomaterials in GC treatment. The review particularly focuses on the combined application of nanocarriers in multiple treatment modalities, such as phototherapy, chemotherapy, and immunotherapy, demonstrating their potential in multimodal treatments. Furthermore, it thoroughly explores the specific challenges that nanocarriers face in GC treatment, such as biocompatibility, drug release control, and clinical translation issues, while providing a systematic outlook on future developments. Additionally, this study emphasizes the potential value and feasibility of nanocarriers in clinical applications, contrasting with most reviews that focus on basic research. Through these innovations, we offer new perspectives and directions for the development of nanotechnology in the treatment of GC.

show abstract

Metallic nanoparticles and treatment of cutaneous leishmaniasis: A systematic review

Cited by 4 publications

References 131 publications

Global Health Priority Box: Discovering Flucofuron as a Promising Antikinetoplastid Compound

Global Health Priority Box: Discovering Flucofuron as a Promising Antikinetoplastid Compound

A Comparative Study of Green and Chemically Prepared PEGylated Zinc Sulfide Nanoparticles (ZnS‐NPs) for Biological Applications

Advancing gastric cancer treatment: nanotechnology innovations and future prospects

Contact Info

Product

Resources

About